ArticleActa neuropathologica2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Open access · hybridAbstract read
In one paragraph
Article in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.Advances in therapy · 2022Pooled it
- Article
- IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Nature cancer · 2026Article
- DNA Methylation Profiling in IDH-Mutant Gliomas: Biological Evolution, Molecular Grading and Clinical Implementation.Neuropathology and applied neurobiology · 2026Review
- Molecular characteristics of isocitrate dehydrogenase 1 R132C-mutant diffuse gliomas: association with TP53 alterations and Li-Fraumeni syndrome.Acta neuropathologica communications · 2026Article
- Integrated transcriptomic analysis reveals KRAS-associated gene activation and epigenetic regulation in mutant IDH1 glioma.Genes & genomics · 2026Article
- Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas.JCO precision oncology · 2026Article
- Immunotherapy and targeted therapy for high grade gliomas: current and future directions.Journal of neuro-oncology · 2025Review
- Predictive efficacy and role of 2HG in MGMT promoter methylation in gliomas: a retrospective study based on MRS and mediator variable analysis.British journal of cancer · 2025Article
- Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.Nature cancer · 2025Article
- Proteomic Analysis Uncovers Enhanced Inflammatory Phenotype and Distinct Metabolic Changes in IDH1 Mutant Glioma Cells.International journal of molecular sciences · 2025Article
- The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Neuro-oncology · 2025Review
- Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.The Journal of biological chemistry · 2025Article
- The IDH1-R132H mutation aggravates cisplatin-induced acute kidney injury by promoting ferroptosis through disrupting NDUFA1 and FSP1 interaction.Cell death and differentiation · 2025Article
- Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.Biomedicines · 2025Article
- Prognostic and predictive determinants in high-grade gliomas: integrating tumor-intrinsic biology with patient and system-level factors.Frontiers in neurology · 2025Review
- The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Neuro-oncology · 2024Review
- Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma.Acta neuropathologica · 2024Article
- Novel immune checkpoint-related gene model to predict prognosis and treatment responsiveness in low-grade gliomas.Heliyon · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors at 20 institutions in 10 countries.
C Mircea S TesileanuDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Wies R VallentgoedDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Marc SansonSorbonne Universités UPMC University of Paris 06, Inserm, CNRS, APHP, Institut du Cerveau et de la Moelle (ICM)-Hôpital Pitié-Salpêtrière, Boulevard de l'hôpital, 75013, Paris, France.
Walter TaalDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Paul M ClementDepartment of Oncology, KU Leuven, Leuven, Belgium.
Wolfgang WickNeurologische Klinik und Nationales Zentrum für Tumorerkrankungen Universitätsklinik, Heidelberg, Germany.
Alba Ariela BrandesMedical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
Jean Francais BaurainMedical Oncology Department, King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium.
Olivier L ChinotNeuro-Oncology Division, Aix-Marseille University, AP-HM, Marseille, France.
Helen WheelerNorthern Sydney Cancer Centre, St Leonards, NSW, 2065, Australia.
Sanjeev GillDepartment Medical Oncology, Alfred Hospital, Melbourne, Australia.
Matthew GriffinDepartment of Clinical Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Leland RogersDepartment of Radiation Oncology, Barrow Neurological Institute, Phoenix, AZ, USA.
Roberta RudàDepartment of Neuro-Oncology, City of Health and Science Hospital and University of Turin, Turin, Italy.
Michael WellerDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Catherine McBainDepartment of Clinical Oncology, The Christie NHS FT, Manchester, UK.
Jaap ReijneveldBrain Tumor Center Amsterdam and Department of Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Roelien H EntingDepartment of Neurology, UMCG, University of Groningen, Groningen, The Netherlands.
Francesca CaparrottiDepartment of Radiation Oncology, University Hospital of Geneva, Geneva, Switzerland.
Thierry LesimpleDepartment of Clinical Oncology, Comprehensive Cancer Center Eugène Marquis, Rennes, France.
Susan ClentonWeston Park Hospital, Sheffield, UK.
Anja GijtenbeekDepartment of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Elizabeth LimDepartment of Clinical Oncology, Plymouth Hospitals NHS Trust, Plymouth, UK.
Filip de VosDepartment of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, The Netherlands.
Paul J MulhollandUniversity College Hospital, London, UK.
Martin J B TaphoornMC Haaglanden, Den Haag, The Netherlands.
Iris de HeerDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Youri HoogstrateDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Maurice de WitDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Lorenzo BoggianiDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Sanne VennekerDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Jan OostingDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Judith V M G BovéeDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Sara ErridgeEdinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburg, UK.
Michael A VogelbaumDepartment of NeuroOncology, Moffitt Cancer Center, Tampa, FL, USA.
Anna K NowakSchool of Medicine and Pharmacology, University of Western Australia, 35 Stirling, Highway Crawley, WA, 6009, Australia.
Warren P MasonPrincess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Johan M KrosDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pieter WesselingDepartment of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
Ken AldapePrincess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Hendrikus J DubbinkDepartment of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Brigitta BaumertDepartment of Radiation-Oncology (MAASTRO), Maastricht University Medical Center (MUMC) and GROW (School for Oncology), Maastricht, The Netherlands.
Vassilis GolfinopoulosEORCT HQ, Brussels, Belgium.
Thierry GorliaEORCT HQ, Brussels, Belgium.
Martin van den BentDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Pim J FrenchDepartment of Neurology, Brain Tumor Center at Erasmus MC Cancer Institute Rotterdam, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. p.french@erasmusmc.nl.ORCID http://orcid.org/0000-0002-0668-9529
Erasmus MC Cancer Institute · NLLeiden University Medical Center · NLErasmus MC · NLUniversity of Toronto · CAAix-Marseille Université · FRAmsterdam UMC Location Vrije Universiteit Amsterdam · NLBarrow Neurological Institute · USCentre Eugène Marquis · FRCentre National de la Recherche Scientifique · FRCliniques Universitaires Saint-Luc · BEGGD Haaglanden · NLHeidelberg University · DEIstituto delle Scienze Neurologiche di Bologna · ITMaastricht University · NLMayo Clinic in Arizona · USMoffitt Cancer Center · USNorthern Cancer Institute · AUNottingham University Hospitals NHS Trust · GBPiedmont Reference Center for Epidemiology and Cancer Prevention · ITPlymouth Hospital · GB
Funding
Single-cell DNA methylation analysis of human cancerZIABC011846 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2018 to 2025
$8.4MUNDERSTANDING THE INTERACTIONS BETWEEN GERMLINE AND SOMATIC ALTERATIONS in the PATHOGENESIS OF GLIOMASR01CA230712 · NCI · MAYO CLINIC ROCHESTER · PI JENKINS, ROBERT B. · 2018 to 2022
$3.3MCancer Research UK 7267Medical Research Council MC_U122861383Medical Research Council MC_UU_12023/10NCI NIH HHS R01 CA230712
Abstract
Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1
Indexed as
MutationAstrocytomaBrain NeoplasmsDNA MethylationHumansIsocitrate DehydrogenasePrognosisSurvival RateIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseAstrocytomaGene expressionGenome-wide DNA methylationIDH1IDH2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.